Changes in serum estrone (E1), estrone sulfate (E1S), and the ratio of E1S/E1 by treatment arm
A. Baseline, 12 mo, and change in serum E1S (ng/mL) by treatment arm | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Baseline | 12 mo | Change (12 mo − baseline) | |||||||||||||||||
Mean | 95% CI | P | Mean | 95% CI | P | Mean | 95% CI | P | ||||||||||||
CEE only (reference) | 105 | 0.65 | 0.59-0.71 | — | 2.58 | 2.29-2.86 | — | 1.93 | 1.65-2.20 | — | ||||||||||
CEE + MPA cyclic | 103 | 0.59 | 0.53-0.64 | 0.14 | 2.86 | 2.53-3.19 | 0.20 | 2.27 | 1.95-2.60 | 0.11 | ||||||||||
CEE + MPA continuous | 113 | 0.60 | 0.55-0.65 | 0.21 | 2.58 | 2.30-2.86 | 0.99 | 1.98 | 1.71-2.25 | 0.79 | ||||||||||
CEE + microP | 107 | 0.69 | 0.63-0.74 | 0.37 | 3.18 | 2.80-3.55 | 0.01 | 2.49 | 2.13-2.85 | 0.01 | ||||||||||
Estrogen + progestogen groups combined | 323 | 0.62 | 0.59-0.66 | 0.45 | 2.87 | 2.68-3.06 | 0.09 | 2.24 | 2.06-2.43 | 0.06 | ||||||||||
B. Baseline, 12 mo, and change in E1 (pg/mL) by treatment arm | ||||||||||||||||||||
n | Baseline | 12 mo | Change (12 mo − baseline) | |||||||||||||||||
Mean | 95% CI | P | Mean | 95% CI | P | Mean | 95% CI | P | ||||||||||||
CEE only (reference) | 105 | 15.8 | 14.3-17.3 | — | 118 | 105-130 | — | 102 | 89.0-115 | — | ||||||||||
CEE + MPA cyclic | 103 | 15.3 | 14.1-16.6 | 0.65 | 111 | 98.3-124 | 0.46 | 95.6 | 83.0-108 | 0.49 | ||||||||||
CEE + MPA continuous | 113 | 16.1 | 14.6-17.6 | 0.75 | 110 | 98.4-121 | 0.37 | 93.8 | 82.5-105 | 0.35 | ||||||||||
CEE + microP | 107 | 17.4 | 15.3-19.6 | 0.21 | 103 | 92.6-114 | 0.08 | 86.0 | 75.5-96.5 | 0.06 | ||||||||||
Estrogen + progestogen groups combined | 323 | 16.3 | 15.3-17.3 | 0.58 | 108 | 101-115 | 0.17 | 91.8 | 85.2-98.4 | 0.15 | ||||||||||
C. Baseline, 12 mo, and change in E1S/E1 [nmol/L]/[nmol/L] by treatment arm | ||||||||||||||||||||
n | Baseline | 12 mo | Change (12 mo − baseline) | |||||||||||||||||
Mean | 95% CI | P | Mean | 95% CI | P | Mean | 95% CI | P | ||||||||||||
CEE only (reference) | 105 | 35.9 | 32.0-39.9 | — | 18.5 | 17.0-20.0 | — | −17.4 | −21.7 to −13.1 | — | ||||||||||
CEE + MPA cyclic | 103 | 31.7 | 26.9-36.6 | 0.19 | 21.9 | 20.0-23.8 | 0.01 | −9.9 | −15.0 to −4.8 | 0.03 | ||||||||||
CEE + MPA continuous | 113 | 32.9 | 29.9-35.9 | 0.22 | 20.2 | 18.2-22.2 | 0.19 | −12.7 | −16.0 to −9.5 | 0.09 | ||||||||||
CEE + microP | 107 | 36.3 | 32.6-40.0 | 0.89 | 25.4 | 23.1-27.8 | 0.0000 | −11.2 | −14.9 to −7.5 | 0.03 | ||||||||||
Estrogen + progestogen groups combined | 323 | 33.6 | 31.4-35.9 | 0.32 | 22.5 | 21.2-23.7 | 0.0001 | −11.3 | −13.6 to −9.0 | 0.01 |
NOTE: P value is for the two-sample t test for the null hypothesis that the mean value for the listed treatment group is equal to the mean value of the CEE-alone treatment group.
Abbreviation: 95% CI, 95% confidence interval.